|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000126218 |
Summary for F10 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000126218 | Gene symbol | F10 |
| Gene name | coagulation factor X | |
| HGNC | 3528 | |
| Entrez ID | 2159 | |
| Gene type | protein_coding | |
| Synonyms | F10| | |
| UniProtAcc | P00742 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000126218 | F10 | DB00025 | Antihemophilic factor, human recombinant | BiotechDrug |
| ENSG00000126218 | F10 | DB00036 | Coagulation factor VIIa Recombinant Human | BiotechDrug |
| ENSG00000126218 | F10 | DB00100 | Coagulation Factor IX (Recombinant) | BiotechDrug |
| ENSG00000126218 | F10 | DB00569 | Fondaparinux | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB01109 | Heparin | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB01225 | Enoxaparin | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB03847 | gamma-carboxy-L-glutamic acid | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB04673 | 4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB05362 | SSR-126517E | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB05713 | LY-517717 | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB06228 | Rivaroxaban | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB06245 | Lanoteplase | BiotechDrug |
| ENSG00000126218 | F10 | DB06406 | Idraparinux | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB06552 | rNAPc2 | BiotechDrug |
| ENSG00000126218 | F10 | DB06605 | Apixaban | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB06635 | Otamixaban | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB06920 | Eribaxaban | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07211 | (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07261 | THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07277 | 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07278 | GW-813893 | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07605 | 2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07629 | N-((1R,2S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07630 | N-((1R,2R)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07800 | N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07804 | 5-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1H-1,2,4-TRIAZOLE-3-SULFONAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07843 | 5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07844 | 6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07847 | 6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4-MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07848 | 5-Chloro-N-{(3S)-1-[(2S)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1H-indole-2-sulfonamide | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07872 | 5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07875 | 5-Chloro-thiophene-2-carboxylic acid ((3S,4S)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amide | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07973 | N-(1-ISOPROPYLPIPERIDIN-4-YL)-1-(3-METHOXYBENZYL)-1H-INDOLE-2-CARBOXAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB07974 | 1-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08143 | 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08173 | 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08174 | 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL)THIOPHENE-2-CARBOXAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08426 | THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08487 | 3-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08488 | 4-{[(E)-2-(5-CHLOROTHIEN-2-YL)VINYL]SULFONYL}-1-(1H-PYRROLO[3,2-C]PYRIDIN-2-YLMETHYL)PIPERAZIN-2-ONE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08495 | 4-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08745 | 4-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB08746 | 1-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-4-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINE | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB09075 | Edoxaban | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB09109 | Turoctocog alfa | BiotechDrug |
| ENSG00000126218 | F10 | DB09141 | Protamine sulfate | BiotechDrug |
| ENSG00000126218 | F10 | DB09258 | Bemiparin | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB09332 | Kappadione | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB11166 | Antithrombin Alfa | BiotechDrug |
| ENSG00000126218 | F10 | DB12364 | Betrixaban | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB12598 | Nafamostat | SmallMoleculeDrug |
| ENSG00000126218 | F10 | DB13149 | Protein S human | BiotechDrug |
| ENSG00000126218 | F10 | DB13150 | Coagulation factor VII human | BiotechDrug |
| ENSG00000126218 | F10 | DB13151 | Anti-inhibitor coagulant complex | BiotechDrug |
| ENSG00000126218 | F10 | DB13152 | Coagulation Factor IX Human | BiotechDrug |
| ENSG00000126218 | F10 | DB13192 | Antihemophilic factor human | BiotechDrug |
| ENSG00000126218 | F10 | DB13884 | Albutrepenonacog alfa | BiotechDrug |
| ENSG00000126218 | F10 | DB13923 | Emicizumab | BiotechDrug |
| ENSG00000126218 | F10 | DB13933 | Nonacog beta pegol | BiotechDrug |
| ENSG00000126218 | F10 | DB13998 | Lonoctocog alfa | BiotechDrug |
| ENSG00000126218 | F10 | DB13999 | Moroctocog alfa | BiotechDrug |
| ENSG00000126218 | F10 | DB14738 | Turoctocog alfa pegol | BiotechDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for F10 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| F10 | 6.66e+02 | -1.12e+00 | 1.67e-01 | -6.72e+00 | 1.80e-11 | 1.57e-09 | KIRC |
| F10 | 1.66e+03 | -1.80e+00 | 5.40e-01 | -3.34e+00 | 8.51e-04 | 3.22e-02 | ACC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| F10 | 5.03e+02 | -1.13e+00 | 3.87e-01 | -2.92e+00 | 3.49e-03 | 8.46e-03 | STAD |
| F10 | 2.04e+02 | -1.76e+00 | 5.75e-01 | -3.06e+00 | 2.18e-03 | 1.15e-02 | ESCA |
| F10 | 3.93e+03 | -3.33e+00 | 5.37e-01 | -6.20e+00 | 5.83e-10 | 8.59e-09 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| F10 | 8.65e+02 | 1.26e+00 | 4.38e-01 | 2.88e+00 | 3.93e-03 | 7.55e-03 | KIRC |
| F10 | 1.47e+02 | -2.85e+00 | 6.07e-01 | -4.69e+00 | 2.72e-06 | 7.45e-05 | BLCA |
| F10 | 1.77e+02 | -2.54e+00 | 1.18e-01 | -2.15e+01 | 6.82e-103 | 2.80e-101 | BRCA |
Top |
Sex-biased somatic mutation for F10 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for F10 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| ACC | cg02747210 | chr13:113122603 | CGI:chr13:113118413-113118698 | promoter | 6.28e-01 | 7.59e-01 | -2.17e+00 | 3.01e-02 | 4.15e-02 | -1.31e-01 |
| ACC | cg03675171 | chr13:113122795 | CGI:chr13:113118413-113118698 | promoter | 5.87e-01 | 7.10e-01 | -2.55e+00 | 1.08e-02 | 2.65e-02 | -1.24e-01 |
| ACC | cg09069900 | chr13:113122650 | CGI:chr13:113118413-113118698 | promoter | 5.79e-01 | 7.18e-01 | -2.22e+00 | 2.65e-02 | 3.96e-02 | -1.39e-01 |
| ACC | cg21714557 | chr13:113122559 | CGI:chr13:113118413-113118698 | promoter | 5.75e-01 | 7.44e-01 | -2.15e+00 | 3.17e-02 | 4.23e-02 | -1.69e-01 |
| KICH | cg21714557 | chr13:113122559 | CGI:chr13:113118413-113118698 | promoter | 7.03e-01 | 5.71e-01 | 2.09e+00 | 3.67e-02 | 4.55e-02 | 1.32e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg09069900 | chr13:113122650 | CGI:chr13:113118413-113118698 | promoter | 4.52e-01 | 6.67e-01 | -3.14e+00 | 1.67e-03 | 2.44e-03 | -2.15e-01 |
| KIRC | cg21714557 | chr13:113122559 | CGI:chr13:113118413-113118698 | promoter | 4.78e-01 | 6.14e-01 | -3.05e+00 | 2.25e-03 | 3.18e-03 | -1.36e-01 |
| KIRC | cg23146998 | chr13:113122601 | CGI:chr13:113118413-113118698 | promoter | 5.89e-01 | 7.33e-01 | -3.22e+00 | 1.29e-03 | 1.95e-03 | -1.44e-01 |
| KIRC | cg02747210 | chr13:113122603 | CGI:chr13:113118413-113118698 | promoter | 6.21e-01 | 7.69e-01 | -4.23e+00 | 2.32e-05 | 5.66e-05 | -1.48e-01 |
| KIRC | cg03675171 | chr13:113122795 | CGI:chr13:113118413-113118698 | promoter | 5.66e-01 | 6.72e-01 | -3.51e+00 | 4.44e-04 | 7.58e-04 | -1.06e-01 |
| HNSC | cg09069900 | chr13:113122650 | CGI:chr13:113118413-113118698 | promoter | 5.09e-01 | 6.62e-01 | -2.57e+00 | 1.01e-02 | 1.29e-02 | -1.53e-01 |
| LUSC | cg26608199 | chr13:113121812 | CGI:chr13:113118413-113118698 | promoter | 6.29e-01 | 8.74e-01 | -3.79e+00 | 1.52e-04 | 8.45e-04 | -2.46e-01 |
| LUSC | cg21367957 | chr13:113121938 | CGI:chr13:113118413-113118698 | promoter | 6.32e-01 | 8.03e-01 | -3.41e+00 | 6.38e-04 | 1.94e-03 | -1.71e-01 |
| COAD | cg03675171 | chr13:113122795 | CGI:chr13:113118413-113118698 | promoter | 2.86e-01 | 3.98e-01 | -3.63e+00 | 2.79e-04 | 7.99e-04 | -1.12e-01 |
| KIRP | cg09069900 | chr13:113122650 | CGI:chr13:113118413-113118698 | promoter | 4.83e-01 | 6.47e-01 | -2.04e+00 | 4.09e-02 | 4.21e-02 | -1.64e-01 |
| KIRP | cg05092353 | chr13:113122699 | CGI:chr13:113118413-113118698 | promoter | 3.98e-01 | 5.23e-01 | -3.19e+00 | 1.43e-03 | 2.47e-03 | -1.25e-01 |
| KIRP | cg21714557 | chr13:113122559 | CGI:chr13:113118413-113118698 | promoter | 4.98e-01 | 6.29e-01 | -2.02e+00 | 4.39e-02 | 4.48e-02 | -1.32e-01 |
| KIRP | cg08548500 | chr13:113122846 | CGI:chr13:113118413-113118698 | UTR,promoter,exon,gene body | 3.98e-01 | 4.98e-01 | -3.59e+00 | 3.35e-04 | 7.21e-04 | -1.00e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg09069900 | chr13:113122650 | CGI:chr13:113118413-113118698 | promoter | 7.75e-01 | 6.12e-01 | 7.43e+00 | 1.13e-13 | 3.72e-13 | 1.63e-01 |
| BRCA | cg21714557 | chr13:113122559 | CGI:chr13:113118413-113118698 | promoter | 6.62e-01 | 5.07e-01 | 7.20e+00 | 5.83e-13 | 1.82e-12 | 1.55e-01 |
| BRCA | cg26608199 | chr13:113121812 | CGI:chr13:113118413-113118698 | promoter | 7.02e-01 | 8.62e-01 | -8.62e+00 | 6.68e-18 | 3.05e-17 | -1.60e-01 |
| BRCA | cg23146998 | chr13:113122601 | CGI:chr13:113118413-113118698 | promoter | 8.18e-01 | 6.99e-01 | 9.41e+00 | 4.96e-21 | 2.93e-20 | 1.19e-01 |
| BRCA | cg02747210 | chr13:113122603 | CGI:chr13:113118413-113118698 | promoter | 8.39e-01 | 7.37e-01 | 9.56e+00 | 1.20e-21 | 7.46e-21 | 1.02e-01 |
| BRCA | cg03675171 | chr13:113122795 | CGI:chr13:113118413-113118698 | promoter | 7.61e-01 | 6.40e-01 | 1.12e+01 | 6.58e-29 | 8.42e-28 | 1.21e-01 |
| HNSC | cg03675171 | chr13:113122795 | CGI:chr13:113118413-113118698 | promoter | 6.21e-01 | 7.33e-01 | -1.98e+00 | 4.78e-02 | 4.82e-02 | -1.12e-01 |
| BLCA | cg03675171 | chr13:113122795 | CGI:chr13:113118413-113118698 | promoter | 4.52e-01 | 5.62e-01 | -2.02e+00 | 4.34e-02 | 4.53e-02 | -1.10e-01 |
Top |
Exon skipping events with PSI in TCGA for F10 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for F10 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for F10 |
| TFs related to F10. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | ZNF235 | F10 | 4.20e+00 | 9.88e-01 | 2.78e+00 | 1.13e-03 | Male-biased |
| DLBC | ZNF287 | F10 | 4.15e+00 | 9.87e-01 | 2.74e+00 | 1.20e-03 | Male-biased |
| DLBC | ZNF487 | F10 | 3.93e+00 | 9.81e-01 | 2.58e+00 | 1.46e-03 | Male-biased |
| GBM | PRDM6 | F10 | 2.02e+00 | 1.10e-03 | 3.90e+00 | 9.81e-01 | Female-biased |
| GBM | ZNF22 | F10 | 2.34e+00 | 2.13e-03 | 3.97e+00 | 9.82e-01 | Female-biased |
| GBM | ZNF235 | F10 | 2.24e+00 | 4.72e-04 | 4.40e+00 | 9.93e-01 | Female-biased |
| GBM | ZNF287 | F10 | 2.26e+00 | 6.71e-04 | 4.31e+00 | 9.91e-01 | Female-biased |
| GBM | ZNF487 | F10 | 2.22e+00 | 1.61e-03 | 3.96e+00 | 9.83e-01 | Female-biased |
| F10 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for F10 |
| RBPs related to ES in F10. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PAAD | BRUNOL6 | exon_skip_101553 | 8.53e+00 | 1.06e-02 | 8.83e+00 | 9.84e-01 | Female-biased |
| F10 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs9514380 | chr13:105346093:C:T | - | 0.167060543764172 | 0.00846742748833835 | PAAD | Female-baised eQTL |
| rs10492530 | chr13:105346218:G:A | - | 0.167060543764172 | 0.00846742748833835 | PAAD | Female-baised eQTL |
| rs9558182 | chr13:103856249:A:C | - | 0.0789351714401523 | 0.00805366730739588 | KIRC | Female-baised eQTL |
| rs12585781 | chr13:103853500:T:G | - | 0.0744550974469212 | 0.0154697032140254 | KIRC | Female-baised eQTL |
| rs56113221 | chr13:103853232:G:T | - | 0.0730707576126766 | 0.0183250581875553 | KIRC | Female-baised eQTL |
| rs9558181 | chr13:103855831:T:C | - | 0.0728427872033317 | 0.0195881809322442 | KIRC | Female-baised eQTL |
| rs12427619 | chr13:103852476:A:G | - | 0.0721197794432921 | 0.0360117491394798 | KIRC | Female-baised eQTL |
| rs9558175 | chr13:103826428:A:G | - | 0.0661234593281992 | 0.0399507705370864 | KIRC | Female-baised eQTL |
| rs57233441 | chr13:103855727:A:G | - | 0.0674013941983233 | 0.0404214702868202 | KIRC | Female-baised eQTL |
| rs1341440 | chr13:103847752:G:T | - | 0.0647011483566354 | 0.0486011964725737 | KIRC | Female-baised eQTL |
| rs61966151 | chr13:103334683:G:T | - | 0.0726625983358331 | 0.0445548211598457 | LUAD | Female-baised eQTL |
| rs72657237 | chr13:107752877:G:A | - | 0.0593868931758121 | 0.0280135490265664 | COAD | Female-baised eQTL |
| rs2211313 | chr13:107753617:G:T | - | 0.0593868931758121 | 0.0280135490265664 | COAD | Female-baised eQTL |
| rs1417902 | chr13:107753032:T:C | - | 0.0590113086745395 | 0.0304050831392775 | COAD | Female-baised eQTL |
| rs2211312 | chr13:107753579:A:C | - | 0.0590113086745395 | 0.0304050831392775 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs9558477 | chr13:105109666:C:T | - | 0.238193723748286 | 6.96941381802418e-05 | READ | Male-baised eQTL |
| rs4147074 | chr13:105030091:T:G | - | -0.153247831220452 | 0.00408719472604708 | READ | Male-baised eQTL |
| rs4378499 | chr13:108659427:G:A | - | 0.161832795374467 | 0.0101234383103733 | READ | Male-baised eQTL |
| rs78933943 | chr13:108662358:C:T | - | 0.16099810091148 | 0.0117953427627806 | READ | Male-baised eQTL |
| rs76766928 | chr13:103652069:G:A | - | 0.219044670098818 | 0.0362984032296106 | READ | Male-baised eQTL |
| rs9558146 | chr13:103652730:G:T | - | 0.219044670098818 | 0.0362984032296106 | READ | Male-baised eQTL |
| rs9586467 | chr13:104314052:A:G | - | 0.128275796825337 | 0.0397096366857065 | READ | Male-baised eQTL |
| rs16964534 | chr13:104296223:G:A | - | 0.128070138614155 | 0.0420960984534433 | READ | Male-baised eQTL |
| rs9989129 | chr13:104298050:C:T | - | 0.128070138614155 | 0.0420960984534433 | READ | Male-baised eQTL |
| rs9562164 | chr13:114224484:A:G | - | 0.166827323638563 | 0.0427650274492784 | READ | Male-baised eQTL |
| rs7987360 | chr13:108105995:A:G | - | -0.134358021253482 | 0.00581169436826426 | PAAD | Male-baised eQTL |
| rs7987674 | chr13:108106085:C:T | - | -0.134358021253482 | 0.00581169436826426 | PAAD | Male-baised eQTL |
| rs7331760 | chr13:108107054:T:C | - | -0.134358021253482 | 0.00581169436826426 | PAAD | Male-baised eQTL |
| rs9520784 | chr13:108107406:A:G | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs4486732 | chr13:108108231:A:G | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs71435172 | chr13:108108343:G:A | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs9520785 | chr13:108109609:T:G | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs1234791 | chr13:108110402:G:A | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs4589412 | chr13:108111206:T:G | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs4304905 | chr13:108111402:A:C | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs4999795 | chr13:108112530:T:G | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs2095297 | chr13:108112545:G:A | - | -0.134403877447645 | 0.00588476838767479 | PAAD | Male-baised eQTL |
| rs6492100 | chr13:108115071:T:A | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs1931345 | chr13:108115472:G:A | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs2151700 | chr13:108115534:C:A | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs184571 | chr13:108116762:C:G | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs4238257 | chr13:108117097:C:T | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs4238258 | chr13:108117149:C:T | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs1931354 | chr13:108117405:G:A | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs1931351 | chr13:108117663:G:T | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs1931350 | chr13:108117770:A:G | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs12871284 | chr13:108118281:T:C | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs12871302 | chr13:108118322:T:C | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs9587511 | chr13:108118526:A:C | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs12870573 | chr13:108118668:A:G | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs333368 | chr13:108119286:C:T | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs4491362 | chr13:108119349:C:T | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs333369 | chr13:108119430:G:A | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs1223974 | chr13:108119719:C:T | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs7988615 | chr13:108120333:T:C | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs1237816 | chr13:108120341:A:G | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs9559256 | chr13:108121473:T:C | - | 0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs9555442 | chr13:108121732:A:G | - | 0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs9559257 | chr13:108121808:G:A | - | 0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs9559258 | chr13:108121832:C:G | - | 0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs333372 | chr13:108121906:A:C | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs231605 | chr13:108121949:C:T | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs333373 | chr13:108122303:G:C | - | -0.127705443612318 | 0.0108912604370781 | PAAD | Male-baised eQTL |
| rs9520790 | chr13:108118748:T:A | - | -0.127902387995223 | 0.0113416705634466 | PAAD | Male-baised eQTL |
| rs75929343 | chr13:108864427:T:C | - | 0.0787034152268478 | 0.0385315266410139 | LIHC | Male-baised eQTL |
| rs76150469 | chr13:108862032:C:T | - | 0.0772303276610408 | 0.0450433076247023 | LIHC | Male-baised eQTL |
| rs76551070 | chr13:108862930:G:A | - | 0.0772303276610408 | 0.0450433076247023 | LIHC | Male-baised eQTL |
| rs56090116 | chr13:108861462:C:T | - | 0.0766223268637334 | 0.0460507620926708 | LIHC | Male-baised eQTL |
| rs60921283 | chr13:108861092:A:G | - | 0.0770248859913302 | 0.0466339773010278 | LIHC | Male-baised eQTL |
| rs58533479 | chr13:108861896:T:C | - | 0.0770248859913302 | 0.0466339773010278 | LIHC | Male-baised eQTL |
| rs74119674 | chr13:108862019:A:G | - | 0.0770248859913302 | 0.0466339773010278 | LIHC | Male-baised eQTL |
| rs74119676 | chr13:108862244:A:G | - | 0.0770248859913302 | 0.0466339773010278 | LIHC | Male-baised eQTL |
| rs6492205 | chr13:109570108:T:C | - | 0.0902512534819066 | 0.0340827190679592 | KIRC | Male-baised eQTL |
| rs7328941 | chr13:107911844:T:C | - | 0.0668451280992303 | 0.0179046466586273 | LUAD | Male-baised eQTL |
| rs7317300 | chr13:107874949:G:A | - | 0.0662441639086504 | 0.0185667658642263 | LUAD | Male-baised eQTL |
| rs57155527 | chr13:107876717:T:C | - | 0.0648598141877278 | 0.0231175665614844 | LUAD | Male-baised eQTL |
| rs11069586 | chr13:105132919:C:G | - | -0.0798030692615204 | 0.036036227736711 | LUAD | Male-baised eQTL |
| rs7327994 | chr13:107890233:G:A | - | 0.0613977173142277 | 0.0370060971826836 | LUAD | Male-baised eQTL |
| rs9555479 | chr13:108525154:C:T | - | 0.0531496023208621 | 0.0441463743200942 | LUAD | Male-baised eQTL |
| rs60516220 | chr13:107896277:G:A | - | 0.0601087093276492 | 0.0443271180474637 | LUAD | Male-baised eQTL |
| rs140621415 | chr13:104493862:G:T | - | 0.111929056407145 | 0.0250707508895113 | COAD | Male-baised eQTL |
| rs9587084 | chr13:106072557:G:C | - | 0.0945775161418568 | 0.0440745086462257 | COAD | Male-baised eQTL |
| rs11842325 | chr13:109235615:A:G | - | 0.0909601151417762 | 0.0479891698360897 | COAD | Male-baised eQTL |
| rs7330669 | chr13:104483247:A:C | - | 0.058314831395249 | 0.0488643079143201 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000126218 |
| CpG Site: cg02747210 | |
| Position to Gene: promoter | |
| Male Effect: -0.448931338784258 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg02747210 | chr13:113122603 | promoter | -0.448931338784258 | 6.76944607598737e-13 | -0.5281155227280168 | 2.4082034257212373e-17 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of F10 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000126218 | F10 | C0005779 | Blood Coagulation Disorders | 1 | CTD_human |
| ENSG00000126218 | F10 | C0015519 | Factor X Deficiency | 1 | CTD_human |
| ENSG00000126218 | F10 | C0040053 | Thrombosis | 1 | CTD_human |
| ENSG00000126218 | F10 | C0087086 | Thrombus | 1 | CTD_human |
